DEBRISOQUINE 4-HYDROXYLASE (CYP2D) LOCUS AND POSSIBLE SUSCEPTIBILITY TO SCHIZOPHRENIA

被引：20
|
作者：
VALLADA, H
COLLIER, D
DAWSON, E
OWEN, M
NANKO, S
MURRAY, R
GILL, M
机构：
[1] TEIKYO UNIV,SCH MED,DEPT PSYCHIAT,TOKYO 173,JAPAN
[2] UNIV WALES COLL MED,DEPT PSYCHOL MED,CARDIFF CF4 4XN,S GLAM,WALES
来源：
LANCET | 1992年 / 340卷 / 8812期
关键词：
D O I：
10.1016/0140-6736(92)93266-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：181 / 182
页数：2
相关论文
共 50 条
  • [31] DNA HAPLOTYPE-DEPENDENT DIFFERENCES IN THE AMINO-ACID-SEQUENCE OF DEBRISOQUINE 4-HYDROXYLASE (CYP2D6) - EVIDENCE FOR 2 MAJOR ALLOZYMES IN EXTENSIVE METABOLIZERS
    PANSERAT, S
    MURA, C
    GERARD, N
    VINCENTVIRY, M
    GALTEAU, MM
    JACQZAIGRAIN, E
    KRISHNAMOORTHY, R
    HUMAN GENETICS, 1994, 94 (04) : 401 - 406
  • [32] Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians
    Ho, SL
    Kung, MHW
    Li, LSW
    Lauder, IJ
    Ramsden, DB
    EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 (03) : 323 - 329
  • [33] ATTEMPTS TO PHENOTYPE HUMAN-LIVER SAMPLES INVITRO FOR DEBRISOQUINE 4-HYDROXYLASE ACTIVITY
    BOOBIS, AR
    HAMPDEN, CE
    MURRAY, S
    BEAUNE, P
    DAVIES, DS
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 19 (06) : 721 - 729
  • [34] ASSAY AND CHARACTERIZATION OF DEBRISOQUINE 4-HYDROXYLASE ACTIVITY OF MICROSOMAL FRACTIONS OF HUMAN-LIVER
    KAHN, GC
    BOOBIS, AR
    MURRAY, S
    BRODIE, MJ
    DAVIES, DS
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 (05) : 637 - 645
  • [35] IMPAIRMENT OF DEBRISOQUINE 4-HYDROXYLASE AND RELATED MONOOXYGENASE ACTIVITIES IN THE RAT FOLLOWING TREATMENT WITH PROPRANOLOL
    MASUBUCHI, Y
    FUJITA, S
    CHIBA, M
    KAGIMOTO, N
    UMEDA, S
    SUZUKI, T
    BIOCHEMICAL PHARMACOLOGY, 1991, 41 (6-7) : 861 - 865
  • [36] THE SPECIFICITY OF INHIBITION OF DEBRISOQUINE 4-HYDROXYLASE ACTIVITY BY QUINIDINE AND QUININE IN THE RAT IS THE INVERSE OF THAT IN MAN
    KOBAYASHI, S
    MURRAY, S
    WATSON, D
    SESARDIC, D
    DAVIES, DS
    BOOBIS, AR
    BIOCHEMICAL PHARMACOLOGY, 1989, 38 (17) : 2795 - 2799
  • [37] CYP2D6-DEBRISOQUINE HYDROXYLASE GENE POLYMORPHISM IN MULTIPLE SYSTEM ATROPHY
    PLANTEBORDENEUVE, V
    BANDMANN, O
    WENNING, G
    QUINN, NP
    DANIEL, SE
    HARDING, AE
    MOVEMENT DISORDERS, 1995, 10 (03) : 277 - 278
  • [38] GENETIC-POLYMORPHISM IN DRUG OXIDATION - INVITRO STUDIES OF HUMAN DEBRISOQUINE 4-HYDROXYLASE AND BUFURALOL 1'-HYDROXYLASE ACTIVITIES
    BOOBIS, AR
    MURRAY, S
    HAMPDEN, CE
    DAVIES, DS
    BIOCHEMICAL PHARMACOLOGY, 1985, 34 (01) : 65 - 71
  • [39] IDENTIFICATION OF THE PRIMARY GENE DEFECT AT THE CYTOCHROME-P450 CYP2D LOCUS
    GOUGH, AC
    MILES, JS
    SPURR, NK
    MOSS, JE
    GAEDIGK, A
    EICHELBAUM, M
    WOLF, CR
    NATURE, 1990, 347 (6295) : 773 - 776
  • [40] CYP2D is involved in neurosteroidogenesis in the brain
    Kishimoto, W
    Hiroi, T
    Osada, M
    Imaoka, S
    Igarashi, T
    Fuane, Y
    CYTOCHROMES P450, BIOCHEMISTRY, BIOPHYSICS AND DRUG METABOLISM, 2003, : 223 - 225
12345